(2S)-2-Amino-1-(2-benzoxazolyl)-1-pentanone | 294885-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: (2S)-2-Amino-1-(2-benzoxazolyl)-1-pentanone
• 英文别名: (2S)-2-amino-1-(1,3-benzoxazol-2-yl)pentan-1-one
• CAS: 294885-30-6
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.25
• InChiKey: FXXDTNPYWHOEGI-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Novel compounds and compositions as cathepsin inhibitors
  申请人：Graupe Michael

  公开号：US20060089357A1

  公开（公告）日：2006-04-27

  The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及新型的cathepsin S抑制剂，其药学上可接受的盐和N-氧化物，它们作为治疗剂的用途以及它们的制备方法。
• Arylacetamido-ketobenzoxazole as cysteine protease inhibitors
  申请人：——

  公开号：US20020156063A1

  公开（公告）日：2002-10-24

  The present invention thus provides compounds of Formula I: 1 pharmaceutical compositions comprising compounds (s) of Formula I and methods of treating diseases associated with cysteine protease activity using pharmaceutical compositions comprising compounds of Formula I.

  因此，本发明提供了式 I 的化合物： 1 包含式I化合物(s)的药物组合物，以及使用包含式I化合物的药物组合物治疗与半胱氨酸蛋白酶活性相关疾病的方法。
• CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1397340A2

  公开（公告）日：2004-03-17
• MORPHOLINE AND TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS
  申请人：Aventis Pharmaceuticals, Inc.

  公开号：EP1515726A1

  公开（公告）日：2005-03-23
• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA CYSTEINE PROTEASE
  申请人：AXYS PHARM INC

  公开号：WO2002023784A2

  公开（公告）日：2002-03-21

  The present invention relates to compounds, compositions and methods for treating diseases associated with cysteine protease activity, particularly diseases associated with activity of cathepsins B, K, L or S.The present invention thus provides compounds of Formula (I): pharmaceutical compositions comprising compounds of Formula (I) and methods of treating diseases associated with cysteine protease activity using pharmaceutical compositions comprising compounds of Formula (I).